RBCL (RBC Life Sciences) Current Deferred Revenue: $0.22 Mil (As of Jun. 2017)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is RBC Life Sciences Current Deferred Revenue?

RBC Life Sciences RBCL +0.14% Current Deferred Revenue is $0.22 Mil as of Jun. 2017.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

RBC Life Sciences's current deferred revenue for the quarter that ended in Jun. 2017 was $0.22 Mil.

RBC Life Sciences Current Deferred Revenue Related Terms

RBC Life Sciences Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for RBC Life Sciences's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RBC Life Sciences Current Deferred Revenue Chart

RBC Life Sciences Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.23 3.68 2.15 0.10 0.01

RBC Life Sciences Quarterly Data
Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.61 0.01 0.01 0.48 0.22
What does a Current Deferred Revenue of $0.22 Mil mean?
RBC Life Sciences (RBCL) has a Current Deferred Revenue of $0.22 Mil as of Jun. 2017. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on RBC Life Sciences and its competitors.
Is RBC Life Sciences' Current Deferred Revenue too high?
RBC Life Sciences' current Current Deferred Revenue is $0.22 Mil.
How does RBC Life Sciences' Current Deferred Revenue compare to SKVI and TISUQ?
RBC Life Sciences' Current Deferred Revenue of $0.22 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Consumer Packaged Goods company?
A good Current Deferred Revenue depends on the Consumer Packaged Goods industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on RBC Life Sciences and its competitors. RBC Life Sciences's current Current Deferred Revenue is $0.22 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RBC Life Sciences stock overvalued right now?
RBC Life Sciences (RBCL) has a current Current Deferred Revenue of $0.22 Mil. The current Current Deferred Revenue is $0.22 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For RBC Life Sciences (RBCL), the current Current Deferred Revenue is $0.22 Mil as of Jun. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

RBC Life Sciences Business Description

Address 2301 Crown Court, Irving, TX, USA, 75038
RBC Life Sciences Inc, through its subsidiaries, is engaged in marketing and distribution of nutritional supplements and personal care products. Its products include herbal formulas, vitamins, minerals, antioxidants, and skin, hair and body care products. It also markets its Nutritional Products in certain international markets through license arrangements. In addition to its Nutritional Products, the company also markets a line of wound care products under the MPM Medical brand name through a U.S. subsidiary.